nilotinib

The drug is used to treat adult patients with chronic myeloid leukemia (CML) that has the Philadelphia chromosome. It is prescribed both at the initial diagnosis of the chronic phase of the disease and in cases where previous therapy (e.g., imatinib) has been ineffective or not tolerated.

Form: capsules, hard

ATC: L01EA03

Manufacturer: Shilpa Medicare Limited (full production cycle; quality control for 'Impurities' parameter; quality control and stability testing (physical and chemical tests))

The drug is used to treat adults with chronic myeloid leukemia (Ph+ CML) in the chronic phase. It is also prescribed in the chronic or accelerated phase if previous therapy (e.g., imatinib) was ineffective or unsuitable for the patient.

Form: capsules, hard

ATC: L01EA03

Manufacturer: Shilpa Medicare Limited (full production cycle; quality control for 'Impurities' parameter; quality control and stability testing (physical and chemical tests))

The drug is prescribed for the treatment of the chronic phase of chronic myeloid leukemia (CML) in adults and children. It is also used in adult and pediatric patients in cases of resistance or intolerance to prior therapy (e.g., imatinib).

Form: capsules, hard

ATC: L01EA03

Manufacturer: Pharos MT Limited (production of finished medicinal product, primary and secondary packaging, batch control, batch release)

The drug is prescribed for the treatment of chronic myeloid leukemia (Ph+ CML) in adults and children. It is used both at the initial diagnosis of the chronic phase of the disease and in the chronic or accelerated phases, if previous therapy (e.g., imatinib) was ineffective or unsuitable for the patient.

Form: capsules, hard

ATC: L01EA03

Manufacturer: Pharos MT Limited (production of finished medicinal product, primary and secondary packaging, batch control, batch release)

The drug is prescribed for the treatment of the chronic phase of chronic myeloid leukemia (CML) in adults and children. It is also used in adult and pediatric patients in cases of resistance or intolerance to prior therapy (including imatinib).

Form: capsules, hard

ATC: L01EA03

Manufacturer: Pharos MT Limited (production of finished medicinal product, primary and secondary packaging, batch control, batch release)

It is used to treat adults with chronic myeloid leukemia (CML) with the Philadelphia chromosome. The drug is prescribed for both newly diagnosed disease and in cases where previous therapy (e.g., imatinib) has been ineffective or is unsuitable for the patient.

Form: capsules, hard

ATC: L01EA03

Manufacturer: Novartis Pharma Stein AG (full-cycle manufacturing)

The drug is used for the treatment of adult patients with chronic myeloid leukemia (Ph+ CML). It is prescribed for both newly diagnosed chronic phase and for chronic or accelerated phase, if previous therapy (e.g., imatinib) has been ineffective or intolerable.

Form: capsules, hard

ATC: L01EA03

Manufacturer: Novartis Pharma Stein AG (full-cycle manufacturing)